title: Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence.
abstract: A single 12.5 mg/kg dose of albendazole (Abz) in tablet form (AbzT) followed 2 weeks later by an equivalent dose of Abz emulsified in 30% soybean oil (AbzE) was administered orally 2 h after the first morning meal to 7 male adult patients with cystic echinococcosis caused by Echinococcus granulosus. Serum samples were taken 1, 3, 5, 7, 8, 9, 11, 14, 18, 24, 36, and 48 h post medication from each patient to measure the serum concentrations of albendazole sulfoxide (AbzSOX), the principal bioactive metabolite of Abz. AbzSOX concentrations were measured by reverse phase HPLC. The data were subjected to pharmacokinetic analysis to compare the relative bioavailability and bioequivalence of AbzT and AbzE. The results demonstrated that the mean peak concentrations (C(max)) for AbzT and AbzE were 1.06+/-0.38 mg/l and 1.71+/-0.47 mg/l, respectively; the area under the concentration-time curves (AUC) were 13.24+/-4.93 mg x h/l and 21.01+/-7.54 mg x h/l, respectively. The relative bioavailability of AbzE was F(Flu)=1.59. Two one-sided tests procedure and (1-2 alpha) 90% confidence interval methods were used to evaluate the bioequivalence of AbzE and AbzT. The results demonstrated that the bioavailability of AbzE was greater than AbzT.
authors.affiliation: Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, 207 Rui Jin Er Lu, Shanghai 200025, China.
authors.forename: Wang
authors.initials: W
authors.lastname: Mingjie
authors.forename: Xiao
authors.initials: X
authors.lastname: Shuhua
authors.forename: Chai
authors.initials: C
authors.lastname: Junjie
authors.forename: Liang
authors.initials: L
authors.lastname: Bin
authors.forename: Fu
authors.initials: F
authors.lastname: Cheng
authors.forename: Shen
authors.initials: S
authors.lastname: Weixia
authors.forename: Peter
authors.initials: P
authors.lastname: Hotez
mesh_terms: D000284:Administration, Oral; D000328:Adult; D015766:Albendazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D001682:Biological Availability; D004443:Echinococcosis / Q000188:drug therapy*; D004655:Emulsions; D006801:Humans; D008297:Male; D051379:Mice; D013024:Soybean Oil; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
chemical_list: D000871:Anthelmintics; D004655:Emulsions; D013024:Soybean Oil; D015766:Albendazole; C027186:albendazole sulfoxide